
Paula Iruzubieta

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/2143797/publications.pdf Version: 2024-02-01



#	Article	IF	CITATIONS
1	Vitamin D deficiency in chronic liver disease. World Journal of Hepatology, 2014, 6, 901.	0.8	83
2	The mitochondrial negative regulator MCJ is a therapeutic target for acetaminophen-induced liver injury. Nature Communications, 2017, 8, 2068.	5.8	77
3	Silencing hepatic MCJ attenuates non-alcoholic fatty liver disease (NAFLD) by increasing mitochondrial fatty acid oxidation. Nature Communications, 2020, 11, 3360.	5.8	73
4	Targeting Hepatic Glutaminase 1 Ameliorates Non-alcoholic Steatohepatitis by Restoring Very-Low-Density Lipoprotein Triglyceride Assembly. Cell Metabolism, 2020, 31, 605-622.e10.	7.2	68
5	Long-term survival after liver transplantation for alcoholic liver disease. World Journal of Gastroenterology, 2013, 19, 9198.	1.4	53
6	Obese patients with NASH have increased hepatic expression of SARS-CoV-2 critical entry points. Journal of Hepatology, 2021, 74, 469-471.	1.8	51
7	Deregulated neddylation in liver fibrosis. Hepatology, 2017, 65, 694-709.	3.6	50
8	LOXL2—A New Target in Antifibrogenic Therapy?. International Journal of Molecular Sciences, 2019, 20, 1634.	1.8	50
9	Hepatic p63 regulates steatosis via IKK \hat{I}^2 /ER stress. Nature Communications, 2017, 8, 15111.	5.8	45
10	miR-873-5p targets mitochondrial GNMT-Complex II interface contributing to non-alcoholic fatty liver disease. Molecular Metabolism, 2019, 29, 40-54.	3.0	35
11	Inhibition of carnitine palmitoyltransferase 1A in hepatic stellate cells protects against fibrosis. Journal of Hepatology, 2022, 77, 15-28.	1.8	31
12	Metabolic subtypes of patients with NAFLD exhibit distinctive cardiovascular risk profiles. Hepatology, 2022, 76, 1121-1134.	3.6	31
13	The Need for Biomarkers in Diagnosis and Prognosis of Drug-Induced Liver Disease: Does Metabolomics Have Any Role?. BioMed Research International, 2015, 2015, 1-8.	0.9	29
14	Metabolic effects of reduced growth hormone action in fatty liver disease. Hepatology International, 2018, 12, 474-481.	1.9	29
15	Increased Expression Profile and Functionality of TLR6 in Peripheral Blood Mononuclear Cells and Hepatocytes of Morbidly Obese Patients with Non-Alcoholic Fatty Liver Disease. International Journal of Molecular Sciences, 2016, 17, 1878.	1.8	28
16	A morphological method for ammonia detection in liver. PLoS ONE, 2017, 12, e0173914.	1.1	28
17	E2F1 and E2F2-Mediated Repression of CPT2 Establishes a Lipid-Rich Tumor-Promoting Environment. Cancer Research, 2021, 81, 2874-2887.	0.4	27
18	A Role for Gut Microbiome Fermentative Pathways in Fatty Liver Disease Progression. Journal of Clinical Medicine, 2020, 9, 1369.	1.0	22

Paula Iruzubieta

#	Article	IF	CITATIONS
19	Neddylation inhibition ameliorates steatosis in NAFLD by boosting hepatic fatty acid oxidation via the DEPTOR-mTOR axis. Molecular Metabolism, 2021, 53, 101275.	3.0	22
20	Magnesium accumulation upon cyclin M4 silencing activates microsomal triglyceride transfer protein improving NASH. Journal of Hepatology, 2021, 75, 34-45.	1.8	21
21	Massive impact of coronavirus disease 2019 pandemic on gastroenterology and hepatology departments and doctors in Spain. Journal of Gastroenterology and Hepatology (Australia), 2021, 36, 1627-1633.	1.4	19
22	Involvement of G protein-coupled receptor kinase 2 (GRK2) in the development of non-alcoholic steatosis and steatohepatitis in mice and humans. Biochimica Et Biophysica Acta - Molecular Basis of Disease, 2018, 1864, 3655-3667.	1.8	18
23	Porto-Sinusoidal Vascular Disease Associated to Oxaliplatin: An Entity to Think about It. Cells, 2019, 8, 1506.	1.8	18
24	Feasibility of large-scale population testing for SARS-CoV-2 detection by self-testing at home. Scientific Reports, 2021, 11, 9819.	1.6	18
25	Plasma betatrophin levels in patients with liver cirrhosis. World Journal of Gastroenterology, 2015, 21, 10662.	1.4	17
26	Inhibition of ATG3 ameliorates liver steatosis by increasing mitochondrial function. Journal of Hepatology, 2022, 76, 11-24.	1.8	16
27	Measurement and clinical usefulness of bilirubin in liver disease. Advances in Laboratory Medicine / Avances En Medicina De Laboratorio, 2021, 2, 352-361.	0.1	13
28	Management of haemostatic alterations and associated disorders in cirrhosis in Spain: A national survey. Digestive and Liver Disease, 2019, 51, 95-103.	0.4	12
29	SARS-CoV-2 massive testing: A window of opportunity to catch up with HCV elimination. Journal of Hepatology, 2021, 74, 966-967.	1.8	12
30	High liver stiffness values by transient elastography related to metabolic syndrome and harmful alcohol use in a large Spanish cohort. United European Gastroenterology Journal, 2021, 9, 892-902.	1.6	12
31	Pathophysiological Mechanisms in Non-Alcoholic Fatty Liver Disease: From Drivers to Targets. Biomedicines, 2022, 10, 46.	1.4	10
32	Prevalence estimation of significant fibrosis because of <scp>NASH</scp> in Spain combining transient elastography and histology. Liver International, 2022, 42, 1783-1792.	1.9	10
33	Changes in Circulating Lysyl Oxidase-Like-2 (LOXL2) Levels, HOMA, and Fibrosis after Sustained Virological Response by Direct Antiviral Therapy. Journal of Clinical Medicine, 2019, 8, 1242.	1.0	5
34	National digestive disease specialists survey on cardiovascular risk management in nonâ€alcoholic fatty liver disease in spanish hospitals. Liver International, 2021, 41, 1243-1253.	1.9	5
35	Boosting mitochondria activity by silencing MCJ overcomes cholestasis-induced liver injury. JHEP Reports, 2021, 3, 100276.	2.6	5
36	Let's leverage SARS-CoV2 vaccination to screen for hepatitis C in Spain, in Europe, around the world. Journal of Hepatology, 2021, 75, 224-226.	1.8	5

Paula Iruzubieta

#	Article	IF	CITATIONS
37	Diagnosis and Characterization of Non-Alcoholic Fatty Liver Disease. , 0, , .		4
38	Biochemical assessment of metabolic associated fatty liver disease. Advances in Laboratory Medicine / Avances En Medicina De Laboratorio, 2021, 2, 199-208.	0.1	3
39	Impact of an acute hemodynamic response-guided protocol for primary prophylaxis of variceal bleeding. World Journal of Clinical Cases, 2018, 6, 611-623.	0.3	3
40	Metabolic-associated fatty liver disease: From simple steatosis toward liver cirrhosis and potential complications. Proceedings of the Third Translational Hepatology Meeting, organized by the Spanish Association for the Study of the Liver (AEEH). GastroenterologAa Y HepatologAa, 2022, 45, 724-734.	0.2	3
41	Neddylation tunes peripheral blood mononuclear cells immune response in COVID-19 patients. Cell Death Discovery, 2022, 8, .	2.0	3
42	Successful Direct Acting Antiviral Therapy in Chronic Hepatitis C Normalizes IFNÎ ³ and IL2 Production in T Cells Together with TLR8 Expression and Functionality in Peripheral Blood Mononuclear Cells. Viruses, 2021, 13, 635.	1.5	2
43	Resistencias al virus de la hepatitis C. Implicaciones y posibilidades terapéuticas. GastroenterologÃa Y HepatologÃa, 2017, 40, 484-494.	0.2	1
44	Valoración bioquÃmica en la enfermedad hepática grasa asociada a la disfunción metabólica. Advances in Laboratory Medicine / Avances En Medicina De Laboratorio, 2021, 2, 209-219.	0.1	1
45	Can NAFLD overwhelm the Spanish healthcare system in the years to come?. Revista Espanola De Enfermedades Digestivas, 2021, 114, 5-9.	0.1	1
46	Bilirrubina: Medición y utilidad clÃnica en la enfermedad hepática. Advances in Laboratory Medicine / Avances En Medicina De Laboratorio, 2021, 2, 362-372.	0.1	0
47	SARS-CoV-2 detection by self-testing: A method to improve surveillance programmes. GastroenterologÃa Y HepatologÃa, 2021, 44, 395-397.	0.2	Ο